Profile | GDS2987 / GI_4504544-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 1.5 | 6 |
GSM215244 | HMVEC_vehicle_rep2 | 17.9 | 42 |
GSM215253 | HMVEC_vehicle_rep3 | 21.2 | 55 |
GSM215254 | HMVEC_atorvastatin_rep1 | ||
GSM215282 | HMVEC_atorvastatin_rep3 | 47.6 | 67 |
GSM215344 | HMVEC_atorvastatin_rep2 | 19.2 | 43 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 16.8 | 32 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 38.9 | 59 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 18.9 | 30 |
GSM215294 | HMVEC_SLx2119_rep1 | 6.9 | 25 |
GSM215295 | HMVEC_SLx2119_rep2 | 20.4 | 39 |
GSM215296 | HMVEC_SLx2119_rep3 | 6.2 | 10 |
GSM215297 | PASMC_vehicle_rep1 | 50 | 59 |
GSM215298 | PASMC_vehicle_rep2 | 26 | 38 |
GSM215310 | PASMC_vehicle_rep3 | 13.7 | 22 |
GSM215311 | PASMC_atorvastatin_rep1 | 26.7 | 43 |
GSM215312 | PASMC_atorvastatin_rep2 | 73.3 | 69 |
GSM215313 | PASMC_atorvastatin_rep3 | 52 | 59 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 46.2 | 59 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 20 | 37 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 32.5 | 49 |
GSM215327 | PASMC_SLx2119_rep1 | 35 | 52 |
GSM215328 | PASMC_SLx2119_rep2 | 22.1 | 38 |
GSM215329 | PASMC_SLx2119_rep3 | 57.1 | 67 |
GSM215330 | Fibroblasts_vehicle_rep1 | 22.5 | 46 |
GSM215331 | Fibroblasts_vehicle_rep2 | ||
GSM215332 | Fibroblasts_vehicle_rep3 | 19.1 | 51 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | ||
GSM215334 | Fibroblasts_atorvastatin_rep2 | 11.4 | 31 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 30.1 | 56 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | ||
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 24.7 | 58 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 8.9 | 25 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 44.3 | 68 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 13.3 | 35 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 15 | 36 |